Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 4/20 | 0.43 |
| ▸ | GABRB2 | P47870 | 4/20 | 0.43 |
| ▸ | ELANE | P08246 | 7/20 | 0.40 |
| ▸ | MTNR1A | P48039 | 6/20 | 0.34 |
| ▸ | MTNR1B | P49286 | 6/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.32 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12355735 | 0.74 | ELANE (0.35) | ELANEKMT2A | |
| SCHEMBL2620973 | 0.69 | MTNR1A (0.57) | GABRA1GABRB2ELANEMTNR1AMTNR1B | |
| SCHEMBL28648952 | 0.69 | GABRA1 (0.39) | GABRA1GABRB2ELANEKMT2AKCNH2 | |
| SCHEMBL28187058 | 0.67 | ELANE (0.45) | GABRA1GABRB2ELANEMTNR1AMTNR1B | |
| SCHEMBL11690968 | 0.65 | GABRA1 (0.43) | GABRA1GABRB2ELANEKCNH2SCN5A | |
| SCHEMBL17853019 | 0.64 | GABRA1 (0.52) | GABRA1GABRB2ELANE | |
| SCHEMBL22800127 | 0.64 | SLC9A1 (0.46) | GABRA1GABRB2ELANE | |
| SCHEMBL25601983 | 0.64 | SMN1; SMN2 (0.47) | GABRA1GABRB2ELANEKMT2A | |
| SCHEMBL23135919 | 0.63 | ELANE (0.45) | GABRA1GABRB2ELANEMTNR1AMTNR1B | |
| SCHEMBL13296096 | 0.63 | GABRA1 (0.50) | GABRA1GABRB2ELANEKCNH2SCN5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230000993-A1 | SILICON BASED DRUG CONJUGATES AND METHODS OF USING SAME | BLINKBIO INC (US) | 2023-01-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230000993-A1 | SILICON BASED DRUG CONJUGATES AND METHODS OF USING SAME | CD44, MSN, AS3MT | GABRA1 3517/4885GABRB2 3402/4885ELANE 2438/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.